)
Tanmay Tiwary specialises in covering equity markets, focusing primarily on sectors like automobile, FMCG, and new-age/internet companies. With almost five years of experience under his belt, Tiwary has previously worked with HT TechCircle (then NewsCorp TechCircle), CNBC TV, and Republic TV. He has also worked with Forbes and Sportskeeda. He holds post-graduate degrees from the University of Leicester and the Indian Institute of Journalism and News Media, Bengaluru.
Tanmay Tiwary specialises in covering equity markets, focusing primarily on sectors like automobile, FMCG, and new-age/internet companies. With almost five years of experience under his belt, Tiwary has previously worked with HT TechCircle (then NewsCorp TechCircle), CNBC TV, and Republic TV. He has also worked with Forbes and Sportskeeda. He holds post-graduate degrees from the University of Leicester and the Indian Institute of Journalism and News Media, Bengaluru.
According to Motilal Oswal, retail mutual fund activity has shown some moderation, particularly in Systematic Investment Plan (SIP) flows, as one-year SIP returns have turned negative.
ACME Solarcontinues to actively bid for utility-scale projects, and incremental awards are essential for building earnings visibility into FY29 and beyond.
Nuvama maintained a 'Buy' rating, underpinned by expectations of a revival in consumption and strategic focus on core categories.
Nuvama flagged 'high valuations' and 'near-term industry weakness' as key reasons for caution, even as structural positives remain intact.
Heavy rains in Q2FY26 adversely affected seasonal categories such as carbonated drinks, ready-to-drink juices, beer, ice creams, and hair/skin summer care products.
Elara Capital cautions that the near-term pricing environment remains weak, with operating leverage and higher costs likely to weigh on profitability in Q2FY26 and potentially spill over into Q3FY26.
Motilal Oswal analysts retained their 'Buy' rating on BEL with a target price of ₹490, based on 45 times September 2027 estimated earnings.
Analysts at Nuvama have revised their target price on the Jindal Steel stock to ₹1,426 from ₹1,193 earlier, valuing it at 7x FY28E EV/Ebitda, and reiterated a 'Buy' rating.
September auto sales expectations: Analysts cite the start of festive sales from September 22, improved finance availability, dealer inventory build-up, and positive rural sentiment as key drivers.
The brokerage highlighted that while the recent Goods and Services Tax (GST) rate cut could provide some relief to the auto sector, its benefit for Hyundai's revenue is limited.
Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.
Nomura maintains a 'Buy' rating on HAL with a target price of ₹6,100, citing the streamlined delivery process and the bolstered order book as key positives.
Analysts at Nomura have initiated coverage of Titan with a 'Buy' rating and a target price of ₹4,275, highlighting the company's strong positioning relative to peers on a risk-weighted basis.
Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.
On Thursday, September 25, 2025, the Tata Motors stock fell as much as 2.59 per cent to an intraday low of ₹665 per share.
Despite a nearly 5x jump in aggregate mcap since FY20, most coverage PSBs still trade at reasonable valuations of 0.8-1x forward P/B & 5-7x FY27E EPS, leaving room for further upside.
Sun Pharma aims to strengthen its domestic formulations business through field force expansion and a generic GLP-1 launch in CY26.
After a flat performance over the past 12 months (up just 3.85%), analysts see Hindalco stock set for a rebound, supported by a combination of commodity dynamics and company-specific factors.
Sri Lotus Developers share price jumped after domestic brokerage Motilal Oswal initiated coverage on the stock with a 'Buy' rating, with a target of ₹250 per share, which reflects an upside of 35%.
Minda Corporation's FY30 revenue target of ₹17,500 cr implies a 28 per cent compound annual growth rate (CAGR) over FY25-30E, while Ebitda is projected at ₹2,100 cr, reflecting a 30 per cent CAGR.